Benzoimidazole derivatives as anticancer agents
US11384081B2 · kind B2 · utility
0Cited by
3References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 20, 2017 |
| Grant date | Jul 12, 2022 |
| Priority date | — |
| Expiry date | Feb 20, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.